Rana R. McKay, MD, University of California San Diego Medical Center

CAR T-Cell Therapy in Metastatic CRPC and Future Directions in Care

August 29th 2023

Closing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.

Ongoing Clinical Trials in the Metastatic CRPC Setting

August 29th 2023

Key opinion leaders in metastatic castration-resistant prostate cancer share insight to key ongoing clinical trials within the landscape.

Potential for CDK4/6 Inhibitors in Metastatic CRPC

August 22nd 2023

Expert panelists briefly reflect on clinical trial data with CDK4/6 inhibitors in metastatic castration-resistant prostate cancer and how their role in this setting might evolve.

Novel Therapeutic Targets in Metastatic CRPC

August 22nd 2023

A broad discussion on emerging therapeutic targets in metastatic castration-resistant prostate cancer and where they may fall within the treatment landscape.

Systemic Treatment Armamentarium in Metastatic HSPC

June 26th 2023

Shared insight on the range of systemic therapy options available to patients who present with metastatic hormone-sensitive prostate cancer.

Overview of Metastatic HSPC: Diagnosis and Risk Stratification

June 26th 2023

Opening their first module on metastatic hormone-sensitive prostate cancer, panelists consider optimal diagnostic and risk stratification strategies for when a patient presents in clinic.

Future of Treating mRCC

July 23rd 2020

Treating Patients With mRCC Beyond Second-Line

July 23rd 2020

Strategies for Switching From Frontline Therapy to Second-Line Therapy in mRCC

July 23rd 2020

Clinical Trials Shaping Treatment in Relapsed/Refractory mRCC

July 23rd 2020

Choosing Second-Line Therapy in Treatment of mRCC

July 23rd 2020

Tailored Therapy Approaches for Upfront mRCC Treatment

July 23rd 2020

Treating Side Effects of Therapy for mRCC with Steroids

July 23rd 2020

Evaluating Safety Profiles of Upfront Regimens for mRCC

July 23rd 2020

Choosing Upfront Therapy for mRCC

July 23rd 2020

CheckMate 9ER: Phase 3 Trial of Frontline Nivolumab + Cabozantinib

July 23rd 2020

Evaluating Long-Term Follow-Up Data for Treatment of mRCC

July 23rd 2020

Patient Factor Consideration for Treatment of mRCC

July 23rd 2020

Applying Clinical Trial Data for Treatment of mRCC

July 23rd 2020

Clinical Trials Defining the NCCN Guidelines for Frontline Treatment of mRCC

July 23rd 2020